N2U0 Stock Overview
A clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Adlai Nortye Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.90 |
| 52 Week High | US$13.20 |
| 52 Week Low | US$6.25 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | -6.03% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| N2U0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 0.2% |
| 1Y | n/a | -17.2% | 8.5% |
Return vs Industry: Insufficient data to determine how N2U0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how N2U0 performed against the German Market.
Price Volatility
| N2U0 volatility | |
|---|---|
| N2U0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: N2U0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine N2U0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 127 | Carsten Lu | www.adlainortye.com |
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1.
Adlai Nortye Ltd. Fundamentals Summary
| N2U0 fundamental statistics | |
|---|---|
| Market cap | €96.34m |
| Earnings (TTM) | -€48.51m |
| Revenue (TTM) | €4.49m |
21.5x
P/S Ratio-2.0x
P/E RatioIs N2U0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N2U0 income statement (TTM) | |
|---|---|
| Revenue | US$5.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$5.00m |
| Other Expenses | US$59.07m |
| Earnings | -US$54.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.47 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,081.30% |
| Debt/Equity Ratio | 72.9% |
How did N2U0 perform over the long term?
See historical performance and comparison